British journal of cancer · 2001

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI

Аннотация

Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concentrations of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel. The effects of zoledronic acid were determined by assessing cell number and rate of apoptosis by evaluating changes in nuclear morphology and using a fluorescence nick translation assay. Zoledronic acid caused a dose- and time-dependent decrease in cell number (P< 0.001) and a concomitant increase in tumour cell apoptosis (P< 0.005). Short-term exposure to zoledronic acid was sufficient to cause a significant reduction in cell number and increase in apoptosis (P< 0.05). These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway. Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel resulted in a 4-5-fold increase in tumour cell apoptosis (P< 0.02). Isobologram analysis revealed synergistic effects on tumour cell number and apoptosis when zoledronic acid and paclitaxel were combined. Short-term treatment with zoledronic acid, which closely resembles the clinical setting, has a clear anti-tumour effect on breast cancer cells. Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. These data suggest that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Full Text

The Full Text of this article is available as a PDF (300.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998 Feb;12(2):220–229. doi: 10.1038/sj.leu.2400892.

Berenbaum M. C. What is synergy? Pharmacol Rev. 1989 Jun;41(2):93–141.

Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M. J. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996 Feb 22;334(8):488–493. doi: 10.1056/NEJM199602223340802.

Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F. H., Delmas P. D., Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997 Sep 15;57(18):3890–3894.

Coxon F. P., Benford H. L., Russell R. G., Rogers M. J. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol. 1998 Oct;54(4):631–638.

Derenne S., Amiot M., Barillé S., Collette M., Robillard N., Berthaud P., Harousseau J. L., Bataille R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999 Dec;14(12):2048–2056. doi: 10.1359/jbmr.1999.14.12.2048.

Diel I. J., Solomayer E. F., Costa S. D., Gollan C., Goerner R., Wallwiener D., Kaufmann M., Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998 Aug 6;339(6):357–363. doi: 10.1056/NEJM199808063390601.

Fisher J. E., Rogers M. J., Halasy J. M., Luckman S. P., Hughes D. E., Masarachia P. J., Wesolowski G., Russell R. G., Rodan G. A., Reszka A. A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):133–138. doi: 10.1073/pnas.96.1.133.

Frith J. C., Mönkkönen J., Blackburn G. M., Russell R. G., Rogers M. J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997 Sep;12(9):1358–1367. doi: 10.1359/jbmr.1997.12.9.1358.

Fromigue O., Lagneaux L., Body J. J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000 Nov;15(11):2211–2221. doi: 10.1359/jbmr.2000.15.11.2211.

Gorczyca W., Melamed M. R., Darzynkiewicz Z. Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay. Toxicol Lett. 1993 Apr;67(1-3):249–258. doi: 10.1016/0378-4274(93)90060-b.

Greco W. R., Bravo G., Parsons J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995 Jun;47(2):331–385.

Hortobagyi G. N., Theriault R. L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J. F., Seaman J., Knight R. D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996 Dec 12;335(24):1785–1791. doi: 10.1056/NEJM199612123352401.

Hughes D. E., Wright K. R., Uy H. L., Sasaki A., Yoneda T., Roodman G. D., Mundy G. R., Boyce B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995 Oct;10(10):1478–1487. doi: 10.1002/jbmr.5650101008.

Kanis J. A., Powles T., Paterson A. H., McCloskey E. V., Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996 Dec;19(6):663–667. doi: 10.1016/s8756-3282(96)00285-2.

Leonessa F., Jacobson M., Boyle B., Lippman J., McGarvey M., Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res. 1994 Jan 15;54(2):441–447.

Luckman S. P., Hughes D. E., Coxon F. P., Graham R., Russell G., Rogers M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998 Apr;13(4):581–589. doi: 10.1359/jbmr.1998.13.4.581.

Magnetto S., Boissier S., Delmas P. D., Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999 Oct 8;83(2):263–269. doi: 10.1002/(sici)1097-0215(19991008)83:2<263::aid-ijc19>3.0.co;2-t.

McCloskey E. V., MacLennan I. C., Drayson M. T., Chapman C., Dunn J., Kanis J. A. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998 Feb;100(2):317–325. doi: 10.1046/j.1365-2141.1998.00567.x.

O'Connor P. M., Jackman J., Bae I., Myers T. G., Fan S., Mutoh M., Scudiero D. A., Monks A., Sausville E. A., Weinstein J. N. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997 Oct 1;57(19):4285–4300.

Paterson A. H., Powles T. J., Kanis J. A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993 Jan;11(1):59–65. doi: 10.1200/JCO.1993.11.1.59.

Rogers M. J., Chilton K. M., Coxon F. P., Lawry J., Smith M. O., Suri S., Russell R. G. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res. 1996 Oct;11(10):1482–1491. doi: 10.1002/jbmr.5650111015.

Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001 Jan 1;19(1):10–17. doi: 10.1200/JCO.2001.19.1.10.

Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D. D., Golub E., Rodan G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991 Dec;88(6):2095–2105. doi: 10.1172/JCI115539.

Shipman C. M., Croucher P. I., Russell R. G., Helfrich M. H., Rogers M. J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998 Dec 1;58(23):5294–5297.

Shipman C. M., Rogers M. J., Apperley J. F., Russell R. G., Croucher P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997 Sep;98(3):665–672. doi: 10.1046/j.1365-2141.1997.2713086.x.

Theriault R. L., Lipton A., Hortobagyi G. N., Leff R., Glück S., Stewart J. F., Costello S., Kennedy I., Simeone J., Seaman J. J. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999 Mar;17(3):846–854. doi: 10.1200/JCO.1999.17.3.846.

Wilson W. H., Berg S. L., Bryant G., Wittes R. E., Bates S., Fojo A., Steinberg S. M., Goldspiel B. R., Herdt J., O'Shaughnessy J. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994 Aug;12(8):1621–1629. doi: 10.1200/JCO.1994.12.8.1621.

Wyllie A. H., Kerr J. F., Currie A. R. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251–306. doi: 10.1016/s0074-7696(08)62312-8.

Yoneda T., Michigami T., Yi B., Williams P. J., Niewolna M., Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer. 2000 Jun 15;88(12 Suppl):2979–2988. doi: 10.1002/1097-0142(20000615)88:12+<2979::aid-cncr13>3.0.co;2-u.

van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Löwik C., Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996 Aug 1;98(3):698–705. doi: 10.1172/JCI118841.

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Ошибки и ограничения

Аннотация

Full Text

Selected References